Sign In
Buy SPRO
$2.15
-0.0600 (-2.71%)
At Close: Jun 23, 2026
Spero Therapeutics: Yesterday's Selloff On Utebzi Approval Seems Bewildering
03:41pm, Thursday, 18'th Jun 2026
Spero Therapeutics, Inc. and partner GSK receive FDA approval for Utebzi, the first oral carbapenem for complicated urinary tract infections, via partnership with GSK. SPRO stands to receive milestone
GSK's Utebzi Wins FDA Nod for Complicated Urinary Tract Infections
10:01am, Thursday, 18'th Jun 2026
GSK wins FDA approval for Utebzi, the first oral carbapenem for complicated UTIs, further expanding its anti-infectives portfolio.
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
04:21pm, Wednesday, 17'th Jun 2026
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO) today announced that the US Food and Drug Administration (FDA) has approved Utebzi, an oral antibiotic for
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
12:36pm, Wednesday, 17'th Jun 2026
CAMBRIDGE, Mass., June 17, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) and GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Uteb
Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update
04:05pm, Wednesday, 13'th May 2026
New Drug Application (NDA) for tebipenem HBr for complicated urinary tract infections (cUTI), including pyelonephritis, is under review at the FDA, with PDUFA date of June 18, 2026 Spero maintains its
Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026
04:05pm, Tuesday, 05'th May 2026
CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare
Spero Therapeutics (NASDAQ:SPRO) versus Mereo BioPharma Group (NASDAQ:MREO) Financial Contrast
02:30am, Saturday, 28'th Mar 2026
Spero Therapeutics (NASDAQ: SPRO - Get Free Report) and Mereo BioPharma Group (NASDAQ: MREO - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the
Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update
04:05pm, Thursday, 26'th Mar 2026
CAMBRIDGE, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rar
Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026
04:05pm, Wednesday, 18'th Mar 2026
CAMBRIDGE, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rar
Spero Therapeutics: Tebipenem's FDA Path Supports A Speculative Buy
08:43am, Wednesday, 11'th Feb 2026
Spero Therapeutics' lead asset is an oral carbapenem tebipenem for cUTI. This asset achieved Phase 3 noninferiority. In fact, this data supports GSK's NDA resubmission strategy. The prior FDA setback
Spero Therapeutics (NASDAQ:SPRO) Stock Price Crosses Below 200 Day Moving Average – What’s Next?
04:33am, Thursday, 05'th Feb 2026
Shares of Spero Therapeutics, Inc. (NASDAQ: SPRO - Get Free Report) crossed below its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $2.2
CAMBRIDGE, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Friday, 28'th Nov 2025
CAMBRIDGE, Mass., Nov. 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rar
Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update
04:05pm, Thursday, 13'th Nov 2025
Results from PIVOT-PO Phase 3 trial evaluating tebipenem HBr in complicated urinary tract infection (cUTI) presented as IDWeek late-breaker in October 2025 Spero's development partner, GSK, plans to s
Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025
04:05pm, Tuesday, 04'th Nov 2025
CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rar
